Jasper Therapeutics Faces Class‑Action Lawsuit Over Securities Violations

Biotech firm Jasper Therapeutics, Inc. (NASDAQ: JSPR) is being sued by shareholders alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b‑5. According to the complaint, Jasper misled investors by failing to maintain sufficient oversight of its third‑party manufacturing partners. This shortfall allegedly put the company’s clinical trials at risk and rendered its public statements false or materially misleading throughout the class period of November 30, 2023 to July 3, 2025. The deadline for eligible shareholders to act is November 18, 2025, and plaintiffs are encouraged to contact DJS Law Group to discuss potential lead‑plaintiff appointments. #JasperTherapeutics #SecuritiesClassAction #InvestorRights #CorporateGovernance #SlimScan #GrowthStocks #CANSLIM